BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 26463234)

  • 1. Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.
    Kishan AU; Park SJ; King CR; Roberts K; Kupelian PA; Steinberg ML; Kamrava M
    Br J Radiol; 2015; 88(1056):20150658. PubMed ID: 26463234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focal high-dose-rate brachytherapy: a dosimetric comparison of hemigland vs. conventional whole-gland treatment.
    Kamrava M; Chung MP; Kayode O; Wang J; Marks L; Kupelian P; Steinberg M; Park SJ; Demanes DJ
    Brachytherapy; 2013; 12(5):434-41. PubMed ID: 23406987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dosimetric comparison of ultra-hypofractionated passively scattered proton radiotherapy and stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
    Kole TP; Nichols RC; Lei S; Wu B; Huh SN; Morris CG; Lee S; Tong M; Mendenhall NP; Dritschilo A; Collins SP
    Acta Oncol; 2015 Jun; 54(6):825-31. PubMed ID: 25227898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From whole gland to hemigland to ultra-focal high-dose-rate prostate brachytherapy: A dosimetric analysis.
    Banerjee R; Park SJ; Anderson E; Demanes DJ; Wang J; Kamrava M
    Brachytherapy; 2015; 14(3):366-72. PubMed ID: 25680768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis.
    Widesott L; Pierelli A; Fiorino C; Lomax AJ; Amichetti M; Cozzarini C; Soukup M; Schneider R; Hug E; Di Muzio N; Calandrino R; Schwarz M
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1589-600. PubMed ID: 21167651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment planning comparison of IMPT, VMAT and 4π radiotherapy for prostate cases.
    Tran A; Zhang J; Woods K; Yu V; Nguyen D; Gustafson G; Rosen L; Sheng K
    Radiat Oncol; 2017 Jan; 12(1):10. PubMed ID: 28077128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing photon and proton-based hypofractioned SBRT for prostate cancer accounting for robustness and realistic treatment deliverability.
    Goddard LC; Brodin NP; Bodner WR; Garg MK; Tomé WA
    Br J Radiol; 2018 May; 91(1085):20180010. PubMed ID: 29436852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dosimetric comparison of tomotherapy and volumetric modulated arc therapy in the treatment of high-risk prostate cancer with pelvic nodal radiation therapy.
    Pasquier D; Cavillon F; Lacornerie T; Touzeau C; Tresch E; Lartigau E
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):549-54. PubMed ID: 22677369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A treatment planning study comparing IMRT techniques and cyber knife for stereotactic body radiotherapy of low-risk prostate carcinoma.
    Scobioala S; Kittel C; Elsayad K; Kroeger K; Oertel M; Samhouri L; Haverkamp U; Eich HT
    Radiat Oncol; 2019 Aug; 14(1):143. PubMed ID: 31399115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative radiotherapy for prostate cancer: a comparison of four consensus guidelines and dosimetric evaluation of 3D-CRT versus tomotherapy IMRT.
    Malone S; Croke J; Roustan-Delatour N; Belanger E; Avruch L; Malone C; Morash C; Kayser C; Underhill K; Li Y; Malone K; Nyiri B; Spaans J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):725-32. PubMed ID: 22444999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosimetric impact of organ at risk daily variation during prostate stereotactic ablative radiotherapy.
    Devlin L; Dodds D; Sadozye A; McLoone P; MacLeod N; Lamb C; Currie S; Thomson S; Duffton A
    Br J Radiol; 2020 Apr; 93(1108):20190789. PubMed ID: 31971829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.
    Fukuda S; Seo Y; Shiomi H; Yamada Y; Ogata T; Morimoto M; Konishi K; Yoshioka Y; Ogawa K
    J Radiat Res; 2014 Nov; 55(6):1114-21. PubMed ID: 24957754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high-risk prostate cancer with seminal vesicles.
    Rana S; Cheng C; Zhao L; Park S; Larson G; Vargas C; Dunn M; Zheng Y
    J Med Radiat Sci; 2017 Mar; 64(1):18-24. PubMed ID: 27741379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knowledge-based radiation therapy (KBRT) treatment planning versus planning by experts: validation of a KBRT algorithm for prostate cancer treatment planning.
    Nwankwo O; Mekdash H; Sihono DS; Wenz F; Glatting G
    Radiat Oncol; 2015 May; 10():111. PubMed ID: 25957871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urethra-Sparing Stereotactic Body Radiation Therapy for Prostate Cancer: Quality Assurance of a Randomized Phase 2 Trial.
    Jaccard M; Zilli T; Dubouloz A; Escude L; Jorcano S; Linthout N; Bral S; Verbakel W; Bruynzeel A; Björkqvist M; Minn H; Tsvang L; Symon Z; Lencart J; Oliveira A; Ozen Z; Abacioglu U; Pérez-Moreno JM; Rubio C; Rouzaud M; Miralbell R
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):1047-1054. PubMed ID: 32535161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosimetry Modeling for Focal Low-Dose-Rate Prostate Brachytherapy.
    Al-Qaisieh B; Mason J; Bownes P; Henry A; Dickinson L; Ahmed HU; Emberton M; Langley S
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):787-93. PubMed ID: 25936808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer.
    Ruggieri R; Naccarato S; Stavrev P; Stavreva N; Fersino S; Giaj Levra N; Mazzola R; Mancosu P; Scorsetti M; Alongi F
    Br J Radiol; 2015 Oct; 88(1054):20140736. PubMed ID: 26235142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon?
    Dubouloz A; Rouzaud M; Tsvang L; Verbakel W; Björkqvist M; Linthout N; Lencart J; Pérez-Moreno JM; Ozen Z; Escude L; Zilli T; Miralbell R
    Radiat Oncol; 2018 Jun; 13(1):114. PubMed ID: 29921291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
    Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VMAT vs. 7-field-IMRT: assessing the dosimetric parameters of prostate cancer treatment with a 292-patient sample.
    Kopp RW; Duff M; Catalfamo F; Shah D; Rajecki M; Ahmad K
    Med Dosim; 2011; 36(4):365-72. PubMed ID: 21377863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.